Contenu :
Format PDF
CEREP
Paris, France, Novembre 12, 2009
Consolidated sales revenues
- Third quarter 2009
Cerep [Euronext Paris: Cerep] consolidated sales revenues reached EUR 6.37 million in the third quarter 2009, decreasing 13.8% compared to EUR 7.39 million earned for the same period of 2008 (-18.1% at cons-tant currency).
- First 9 months 2009
At September 30, 2009, total sales revenues reached EUR 18.71 million compared to EUR 21.63 million in 2008, thus reflecting a decrease of 13.5% (-20.1% on a constant currency basis).
Thierry Jean, Chairman and CEO said: "The sales revenues for the third quarter and the first 9 months of 2009 confirm a lower demand resulting from budget restrictions or delayed spending of pharmaceutical and biotechnology companies. Some of these groups experience significant restructurings and are impacted by mergers and acquisitions. Pharmaceutical industry is facing major challenges as it has to strengthen its drug portfolio while decreasing costs, with a direct impact on outsourcing in preclinical services and an increased cost pressure.
We do not anticipate a noticeable uptrend during the fourth quarter. Nonetheless we believe that this situa-tion is temporary and might improve in 2010. On a long term basis, past or current reorganizations in the pharmaceutical industry should result in an increased level of outsourcing in drug discovery services. Our unique industrialized platform and improved productivity achieved over the past years ideally position Ce-rep to capture upcoming R&D markets."
Cash position
The Group's cash and cash equivalent (excluding treasury shares) is EUR 18.50 million at September 30, 2009 compared to EUR 18.95 million at June 30, 2009.
Recent events
- Cerep has recently signed a lease agreement for laboratory spaces in Shanghai. The laboratory fitting should be achieved at the end of 2009. The Chinese affiliate is scheduled to start in the first quarter of 2010.
- On October 13, 2009 Cerep announced the signature of a BioPrint® evaluation licence with Ro-che.Under the terms of the agreement Roche will be granted access to BioPrint® data and pharmaco-informatic tools for a maximum of two years and a limited number of users. At the end of the evaluation phase, Roche will have the option to subscribe a perpetual licence at a predetermined price.
Outlook
In a difficult economic environment impacting all Cerep's clients, the Group is not anticipating an increase in demand during the fourth quarter of the year. As a consequence, Cerep is reinforcing costs savings efforts.
In parallel, Cerep is pursuing its development to capture new market shares in outsourced drug discovery services.The establishment in China will certainly be a major step of Cerep expansion over the coming years.
© La Tribune Wire
Retrouvez les communiqués de CEREP sur www.LaTribuneWire.com
Pied de page :
